Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

Raises 2025 Financial Guidance Ranges for Total Revenue to $1,150 - $1,225 million, Representing YoY Growth of 16% - 23%, Adjusted EBITDA of $755 - $805 million, Representing YoY Growth of 24% - 32%, ...

The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type ...

Bristol Myers Squibb’s Cobenfy achieved an 8.4-point PANSS improvement over placebo after five weeks in a phase 3 trial that ...

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care ...

Licensing deals have risen in prominence in a restrained market environment. Is it desperation, or an important part of the ...

This was the stock's second consecutive day of gains.

By Sneha S K and Sriparna Roy (Reuters) -The U.S. Food and Drug Administration said on Friday that it has approved an ...

The U.S. Justice Department said on Tuesday it entered an agreement to share $50 million in forfeited assets with Estonia in ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

Emerging evidence supports the argument that psoriatic arthritis arises from two pathways and that affected immune cells may ...